// App-Quantinova.ai

EP1026 : CHARACTERIZATION OF OCULAR ADVERSE EVENTS IN PATIENTS RECEIVING BELANTAMAB MAFADOTIN FOR ≥12 MONTHS: POST-HOC ANALYSIS OF DREAMM-2 STUDY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

Researchers

Presenter

  • Sagar Lonial

Principal Investigators

  • Praneetha Thulasi

  • Ashraf Z. Badros

  • Bennie H. Jeng

  • Natalie S. Callander

  • Douglas Sborov

  • Brian E. Zaugg

  • Rakesh Popat

  • Simona Degli Esposti

  • January Baron

  • Allison Doherty

  • Eric Lewis

  • Joanna Opalinska

  • Prani Paka

  • Trisha Piontek

  • Ira Gupta

  • Asim Farooq

  • Andrzej Jakubowiak

Medical Centers

  • Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States

  • R&D, GlaxoSmithKline, Collegeville, PA, United States,

  • University of Wisconsin Carbone Cancer Center, Madison/WI/US

  • University College London Hospitals NHS Trust, London, United Kingdom

  • GlaxoSmithKline, Upper Providence, PA, United States.

  • GlaxoSmithKline, Research Triangle Park, NC, United States.

  • Emory Winship Cancer Institute,Atlanta GA,United States

  • University of Maryland School of Medicine, Baltimore, MD

  • John A. Moran Eye Center, University of Utah, Salt Lake, Utah, United States

  • Emory Eye Center, Emory University,Atlanta, GA,United States

  • NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London

  • Rush University Medical Center, Chicago, Illinois, United States

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • GSK2857916

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT03525678

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved